The FDA's Orphan Drug Designation (ODD) is a significant policy introduced to encourage the development of drugs for rare diseases. Since the Orphan Drug Act was enacted in 1983, this policy has successfully leveraged industry resources towards rare disease research through a "package of incentives" including tax credits, special research grants, seven years of market exclusivity, and priority review pathways. To date, it has facilitated the approval of over 600 innovative drugs, transforming the treatment landscape for approximately 5% of the world's rare diseases (out of over 7,000 known conditions) from "untreatable" to "treatable."
The ODD for GC310 Adeno-Associated Virus Injection represents another major breakthrough for Genecradle Therapeutics in the field of gene therapy. Previously, Genecradle's Pompe disease gene therapy, GC301 Adeno-Associated Virus Injection, had already received ODD. This latest approval not only solidifies Genecradle Therapeutics' leading position in the field of rare disease gene therapy but also highlights the company's innovative capabilities in gene therapy drug development and advances its global strategy. With these dual ODD recognitions as a driving force, Genecradle Therapeutics will accelerate the clinical trials of GC301 and GC301 and other pipeline products, practicing its mission of "originating from needs, benefiting patients," and bringing "Made in China" treatment hopes to patients worldwide.
About Hepatolenticular Degeneration
Hepatolenticular degeneration, also known as Wilson disease (WD), is an autosomal recessive genetic disorder caused by mutations in the ATP7B gene. The functional deficiency of the ATP7B gene leads to copper metabolism disorders, resulting in the abnormal accumulation of toxic free copper ions in the body, primarily deposited in the liver, central nervous system, kidneys, and cornea, causing a range of progressively worsening pathological changes, including liver cirrhosis, neuropsychiatric disorders, kidney damage, and the characteristic Kayser-Fleischer (K-F) ring in the cornea. Globally, the prevalence of WD is approximately 1 in 30,000 to 100,000 people, with a carrier rate of the pathogenic gene of about 1 in 90. The disease can affect individuals across a wide age range but is primarily concentrated in children and adolescents, with the highest incidence between the ages of 5 and 35. It is noteworthy that, according to epidemiological studies, the incidence and carrier rates of WD in Asian regions, including China, may be higher than in Western countries, with some data suggesting that the incidence in China may be close to one in ten thousand.
About GC310 Adeno-Associated Virus Injection
GC310 Adeno-Associated Virus Injection is a gene therapy drug independently developed by Genecradle Therapeutics for the treatment of hepatolenticular degeneration. This therapy precisely delivers a functional miniATP7B gene, enabling the target tissue to express the biologically active miniATP7B copper ion transporter protein through a single treatment, restoring copper ion metabolism and increasing ceruloplasmin levels, potentially improving the condition fundamentally. In preclinical studies, GC310 Injection has demonstrated good drug safety and significant efficacy. Experimental results show that the drug can effectively reduce liver and urinary copper levels in hepatolenticular degeneration mouse models, increase ceruloplasmin activity, and significantly improve symptoms. The gene therapy has received tacit approval for registration of clinical trials from the National Medical Products Administration and will soon initiate a multicenter registration clinical trial, led by Peking Union Medical College Hospital. Please stay tuned for further announcements.
About Genecradle Therapeutics
Beijing Genecradle Therapeutics Technology Co., Ltd. is a national high-tech enterprise with core business in the development of gene therapy drugs mediated by AAV vector delivery technology. The company is committed to advancing rare disease gene drugs from the laboratory to clinical and market applications, benefiting patients and their families. It specializes in the development of gene therapy drugs for genetic neuromuscular diseases, inherited metabolic diseases, lysosomal diseases, and ophthalmic diseases. By promoting the research and clinical application of rare disease gene drugs, the company aims to deepen the understanding of health and life, transitioning gene therapy technology and products from rare diseases to the treatment and rehabilitation of chronic and other major diseases.